Several interesting combinations of therapies with Calquence for patients with CLL

Calquence, acalabrutinib, is a specific inhibitor of Bruton tyrosine kinase and a very effective and well-tolerated drug in treating CLL. At this year’s ASH Congress, several studies of combination therapies were presented, showing, according to Matthew Davids, that acalabrutinib will be a part of the combinations in the future. In this MEDtalk, Matthew Davids from the Dana Faber Cancer Institute in Boston, USA, gives his perspective on the combinations with acalabrutinib.